Editorial Board Members’ Collection Series: Novel Drug Delivery Systems

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (28 September 2023) | Viewed by 3115

Special Issue Editors

The Novel Drug & Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON P3E 2C6, Canada
Interests: ADME; toxicology; drug repurposing; drug delivery systems; antimicrobial resistances; infectious diseases and drug interactions
Institute of Nanoscience and Nanotechnology, National Centre for Scientific Research “Demokritos”, P.O. Box 60037, 15310 Aghia Paraskevi, Attiki, Greece
Interests: functional liposomes; functional dendritic polymers; nano-sized drug delivery systems; drug targeting; triggered drug release
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This topic is intended to report basic knowledge on the area of novel drug and vaccine delivery systems. These Novel delivery systems should include the formulation, Physicochemical, biological properties and various strategies for development, criteria for selection of drugs and vaccines, their formulations approaches and evaluation of novel delivery systems. The issue focus in particular on ocular, intrauterine, nasopulmonary, gastroretentive, transdermal; implantable, mucosal, microencapsulation, 3D printing and smart drug delivery systems.

  1. Controlled Drug Delivery System
  2. Smart Drug Delivery Systems
  3. Solid Oral Controlled-Release Formulations
  4. Controlled Therapeutic Delivery in Wound Healing
  5. Parenteral Drug Delivery and Delivery Systems
  6. Vaginal Drug Delivery Systems
  7. Targeted drug Delivery
  8. Ocular Drug Delivery Systems
  9. Intrauterine Drug Delivery Systems
  10. Vaccine Delivery System
  11. Transdermal Drug Delivery Systems
  12. Gastroretentive drug delivery systems
  13. Nasal drug delivery system
  14. Pulmonary drug delivery system
  15. Microencapsulation
  16. Mucosal Drug Delivery system
  17. Implantable Drug Delivery Systems
  18. Artificial intelligence in drug delivery modeling
  19. Artificial Intelligence and 3D printing technology for drug delivery system and devices
  20. Regulatory Considerations in Novel Drug Delivery Systems

Prof. Dr. Abdelwahab Omri
Dr. Dimitris Tsiourvas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery system
  • infectious diseases
  • antibiotic resistance
  • biofilm
  • pulmonary infection

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 6019 KiB  
Article
Norcantharidin Nanoemulsion Development, Characterization, and In Vitro Antiproliferation Effect on B16F1 Melanoma Cells
Pharmaceuticals 2023, 16(4), 501; https://doi.org/10.3390/ph16040501 - 28 Mar 2023
Cited by 5 | Viewed by 1343
Abstract
Melanoma is a highly lethal type of cancer that has had an increase in incidence in the last decades. Nevertheless, current therapies lack effectiveness and have highly disabling side effects, which calls for new therapeutic strategies. Norcantharidin (NCTD) is an acid derivative with [...] Read more.
Melanoma is a highly lethal type of cancer that has had an increase in incidence in the last decades. Nevertheless, current therapies lack effectiveness and have highly disabling side effects, which calls for new therapeutic strategies. Norcantharidin (NCTD) is an acid derivative with potential antitumor activity isolated from natural blister beetles. However, its solubility limitations restrict its use. To address this issue, we developed an oil-in-water nanoemulsion using commonly available cosmetic ingredients, which increased NCTD solubility 10-fold compared to water. The developed nanoemulsion showed a good droplet size and homogeneity, with adequate pH and viscosity for skin application. In vitro drug release studies showed a sustained release profile, ideal for prolonged therapeutic effects. Accelerated stability studies proved that the formulation was reasonably stable under stress conditions, with particle separation fingerprints, instability index, particle size, and sedimentation velocity analyses being conducted. To assess the therapeutic potential of the developed formulation, in vitro studies were conducted on melanoma B16F1 cells; results showed an IC50 of 1.026 +/− 0.370 mg/kg, and the cells’ metabolic activity decreased after exposure to the NCTD nanoemulsion. Hence, a new “easy-to-make” nanoformulation with therapeutic potential on melanoma cells was developed, as a possible adjuvant for future melanoma treatment. Full article
Show Figures

Figure 1

18 pages, 13226 KiB  
Article
Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action
Pharmaceuticals 2023, 16(2), 258; https://doi.org/10.3390/ph16020258 - 08 Feb 2023
Viewed by 1435
Abstract
Electrospraying (ES) technology is considered an efficient micro/nanoparticle fabrication technique with controlled dimensions and diverse morphology. Gelurice® 48/16 (GLR) has been employed to stabilize the aqueous dispersion of Celecoxib (CXB) for enhancing its solubility and oral bioavailability. Our formula is composed of [...] Read more.
Electrospraying (ES) technology is considered an efficient micro/nanoparticle fabrication technique with controlled dimensions and diverse morphology. Gelurice® 48/16 (GLR) has been employed to stabilize the aqueous dispersion of Celecoxib (CXB) for enhancing its solubility and oral bioavailability. Our formula is composed of CXB loaded in polyvinylpyllodine (PVP) stabilized with GLR to formulate microparticles (MPs) (CXB-GLR-PVP MPs). CXB-GLR-PVP MPs display excellent in vitro properties regarding particle size (548 ± 10.23 nm), zeta potential (−20.21 ± 2.45 mV), and drug loading (DL, 1.98 ± 0.059 mg per 10 mg MPs). CXB-GLR-PVP MPs showed a significant (p < 0.05) higher % cumulative release after ten minutes (50.31 ± 4.36) compared to free CXB (10.63 ± 2.89). CXB exhibited good dispersibility, proved by X-ray diffractometry (XRD), adequate compatibility of all components, confirmed by Fourier-Transform Infrared Spectroscopy (FTIR), and spherical geometry as revealed in scanning electron microscopy (SEM). Concerning our anti-inflammatory study, there was a significant decrease in the scores of the inflammatory markers’ immunostaining in the CXB-GLR-PVP MPs treated group. Also, the amounts of the oxidative stress biomarkers, as well as mRNA expression of interleukins (IL-1β and IL-6), considerably declined (p < 0.05) in CXB-GLR-PVP MPs treated group alongside an enhancement in the histological features was revealed. CXB-GLR-PVP MPs is an up-and-coming delivery system that could be elucidated in future clinical investigations. Full article
Show Figures

Figure 1

Back to TopTop